Bedaquiline: Uses, Interactions and Safety

Uses

Bedaquiline is used within an effective multidrug regimen for pulmonary tuberculosis resistant to at least rifampicin and isoniazid. It is not a treatment for latent infection, drug-sensitive TB or non-tuberculous mycobacteria. Specialist teams choose the companion medicines according to susceptibility and current TB guidance.

Administration

Tablets are taken with food. Administration methods differ between tablet strengths, so swallowing difficulties should be discussed with the team rather than solved by crushing any tablet. Directly observed treatment and completion of the full regimen help prevent failure and resistance. Age and weight eligibility differ between US and European products.

Safety

Bedaquiline can prolong the QT interval. An ECG, electrolytes and liver tests are checked before treatment and during follow-up. Fainting or palpitations require prompt assessment. Jaundice, dark urine or persistent appetite loss and nausea may signal liver injury. The unexplained mortality imbalance in an earlier trial remains described in the label; it is not a reason to abandon a necessary regimen independently.

Interactions

Strong or moderate CYP3A inducers, including rifamycins and certain anticonvulsants, can reduce bedaquiline exposure and should be avoided. CYP3A inhibitors need close safety monitoring. Other QT-prolonging medicines can add to rhythm risk. Moxifloxacin or levofloxacin may nevertheless be intentional TB partners under ECG monitoring. Isoniazid, pyrazinamide and ethambutol are not automatically prohibited combinations.

Pregnancy and breastfeeding

Human pregnancy data are insufficient to define drug-specific risk. Decisions balance this uncertainty against resistant TB. The US label generally advises against breastfeeding unless infant formula is unavailable, with infant monitoring if exposure occurs.

Adverse effects

Nausea, joint pain, headache, vomiting, abdominal discomfort and abnormal liver tests are reported. QT changes may be symptom-free, which is why scheduled monitoring matters. Avoid alcohol and tell the team about every prescription, non-prescription product and planned medication change.

Sources

• SIRTURO (bedaquiline) tablets: US prescribing information
• SIRTURO: EMA product information
• Turkish Ministry of Health tuberculosis diagnosis and treatment guideline (2026)
• WHO ATC/DDD Index 2026: J04AK
• Posaconazole delayed-release tablets and oral suspension: US prescribing information
• CRESEMBA: EMA product information, summary of product characteristics
• XTANDI (enzalutamide): EMA product information
• ERLEADA (apalutamide): EMA product information
• KISQALI (ribociclib): US prescribing information